Trial Profile
A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 16 Sep 2019 Results published in the Antimicrobial Agents and Chemotherapy.
- 28 Apr 2014 New trial record